A clinical study and future prospects for bioactive compounds and semi-synthetic molecules in the therapies for Huntington's disease
- PMID: 37698833
- DOI: 10.1007/s12035-023-03604-4
A clinical study and future prospects for bioactive compounds and semi-synthetic molecules in the therapies for Huntington's disease
Abstract
A neurodegenerative disorder (ND) refers to Huntington's disease (HD) which affects memory loss, weight loss, and movement dysfunctions such as chorea and dystonia. In the striatum and brain, HD most typically impacts medium-spiny neurons. Molecular genetics, excitotoxicity, oxidative stress (OS), mitochondrial, and metabolic dysfunction are a few of the theories advanced to explicit the pathophysiology of neuronal damage and cell death. Numerous in-depth studies of the literature have supported the therapeutic advantages of natural products in HD experimental models and other treatment approaches. This article briefly discusses the neuroprotective impacts of natural compounds against HD models. The ability of the discovered natural compounds to suppress HD was tested using either in vitro or in vivo models. Many bioactive compounds considerably lessened the memory loss and motor coordination brought on by 3-nitropropionic acid (3-NP). Reduced lipid peroxidation, increased endogenous enzymatic antioxidants, reduced acetylcholinesterase activity, and enhanced mitochondrial energy generation have profoundly decreased the biochemical change. It is significant since histology showed that therapy with particular natural compounds lessened damage to the striatum caused by 3-NP. Moreover, natural products displayed varying degrees of neuroprotection in preclinical HD studies because of their antioxidant and anti-inflammatory properties, maintenance of mitochondrial function, activation of autophagy, and inhibition of apoptosis. This study highlighted about the importance of bioactive compounds and their semi-synthetic molecules in the treatment and prevention of HD.
Keywords: Herbal medicine; Huntington’s disease; Mitochondrial dysfunction; Natural compounds; Neurodegenerative disorders; Neuroprotective; Nutraceuticals.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Protective Effect of Natural Products against Huntington's Disease: An Overview of Scientific Evidence and Understanding Their Mechanism of Action.ACS Chem Neurosci. 2021 Feb 3;12(3):391-418. doi: 10.1021/acschemneuro.0c00824. Epub 2021 Jan 21. ACS Chem Neurosci. 2021. PMID: 33475334 Review.
-
Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease.J Med Food. 2009 Jun;12(3):591-600. doi: 10.1089/jmf.2008.0028. J Med Food. 2009. PMID: 19627208
-
L-theanine, a Component of Green Tea Prevents 3-Nitropropionic Acid (3-NP)-Induced Striatal Toxicity by Modulating Nitric Oxide Pathway.Mol Neurobiol. 2017 Apr;54(3):2327-2337. doi: 10.1007/s12035-016-9822-5. Epub 2016 Mar 9. Mol Neurobiol. 2017. PMID: 26957301
-
Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.Brain Res Bull. 2012 Mar 10;87(4-5):397-405. doi: 10.1016/j.brainresbull.2012.01.003. Epub 2012 Jan 11. Brain Res Bull. 2012. PMID: 22245028
-
Mitochondrial targeted antioxidants as potential therapy for huntington's disease.Pharmacol Rep. 2024 Aug;76(4):693-713. doi: 10.1007/s43440-024-00619-z. Epub 2024 Jul 9. Pharmacol Rep. 2024. PMID: 38982016 Review.
Cited by
-
Neuroinflammation and neurodegeneration in Huntington's disease: genetic hallmarks, role of metals and organophosphates.Neurogenetics. 2025 Jan 17;26(1):21. doi: 10.1007/s10048-025-00801-2. Neurogenetics. 2025. PMID: 39820855 Review.
-
The role of Panax ginseng in neurodegenerative disorders: mechanisms, benefits, and future directions.Metab Brain Dis. 2025 Apr 15;40(4):183. doi: 10.1007/s11011-025-01610-0. Metab Brain Dis. 2025. PMID: 40232582 Review.
-
Recent Developments in Nanoparticle Formulations for Resveratrol Encapsulation as an Anticancer Agent.Pharmaceuticals (Basel). 2024 Jan 18;17(1):126. doi: 10.3390/ph17010126. Pharmaceuticals (Basel). 2024. PMID: 38256959 Free PMC article. Review.
-
Synthetic and semi-synthetic antioxidants in medicine and food industry: a review.Front Pharmacol. 2025 Jul 22;16:1599816. doi: 10.3389/fphar.2025.1599816. eCollection 2025. Front Pharmacol. 2025. PMID: 40766767 Free PMC article. Review.
-
Sulforaphane and Brain Health: From Pathways of Action to Effects on Specific Disorders.Nutrients. 2025 Apr 15;17(8):1353. doi: 10.3390/nu17081353. Nutrients. 2025. PMID: 40284217 Free PMC article. Review.
References
-
- Krobitsch S, Kazantsev AG (2011) Huntington’s disease: from molecular basis to therapeutic advances. Int J Biochem Cell Biol 43:20–24. https://doi.org/10.1016/J.BIOCEL.2010.10.014 - DOI - PubMed
-
- Kumar P, Kalonia H, Kumar A (2010) Huntington’s disease: pathogenesis to animal models. Pharmacol Rep 62:1–14. https://doi.org/10.1016/S1734-1140(10)70238-3 - DOI - PubMed
-
- Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10(4):204–16. https://doi.org/10.1038/nrneurol.2014.24
-
- Gil JM, Rego AC (2008) Mechanisms of neurodegeneration in Huntington’s disease. Eur J Neurosci 27:2803–2820. https://doi.org/10.1111/J.1460-9568.2008.06310.X - DOI - PubMed
-
- Bashir H (2019) Emerging therapies in Huntington’s disease. Expert Rev Neurother 19:983–995. https://doi.org/10.1080/14737175.2019.1631161 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous